Evaluation of Serum Level of Calprotectin in Patients with Psoriasis and Its Relation to The Clinical Severity of The Disease | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 13, Volume 76, Issue 4, July 2019, Page 3919-3923 PDF (290.58 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2019.41574 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Amr Mohamed Zaki1; Mohamed Abdelmawgoud Amer1; Nagah Mohamed A. Mohamed2; Mohamed Ahmed El-saeed Abdelkhalik  1
| ||||
| 1Departments of Dermatology & Venereology, Faculty of Medicine, Al-Azhar University | ||||
| 2Departments of Clinical Pathology & Immunology, Faculty of Medicine, Al-Azhar University | ||||
| Abstract | ||||
| Background: Psoriasis is a common chronic immune mediated papulosquamous disease. Its prevalence around 2-3% of the general population,and is characterized by an exaggerated proliferation of keratinocytes secondary to an activated immune system. Objective: the aim of this work was to investigate the relationship between serum Calprotectin and psoriasis vulgaris and to correlate with disease severity. Patients and Methods: the present study was conducted on 50 patients with psoriasis (group A) and 30 healthy control subjects (group B). Both groups were subjected to full history taking, clinical examination and estimation of serum level of calprotectin using ELISA technique. PASI score was used to assess disease severity in group A. Results: calprotectin level was significantly higher in cases group than in control group. A positive statistical correlation between the calprotectin level and the disease severity (PASI score) was observed but not with age, sex, nor duration of disease. Conclusion: calprotectin can be used as a marker of psoriasis severity and progression. Calprotectin may play a role in the pathogenesis of psoriasis. | ||||
| Keywords | ||||
| Calprotectin; Psoriasis; autoimmune diseases | ||||
|
Statistics Article View: 372 PDF Download: 684 |
||||
